https://www.selleckchem.com/products/ABT-888.html
08 log copies/mL; IQR 0-4.19), compared with placebo (3.31 log copies/mL; IQR 1.18-4.75). At day 7, there was still a greater median percentage (log copies/mL) decrease in salivary viral load over time in the CDCM group (-58.62%; IQR -100% to -34.36%) compared with the placebo group (-50.62%; IQR -100% to -27.66%). These results were confirmed by the per-protocol analysis. This trial supports the relevance of using CDCM on day 1 (4hours after the initial dose) to reduce the SARS-CoV-2 viral load in saliva. For long-term effect (7days),
Like
Comment
Share
